Coagulation FactorXIIa-kinin-mediated contribution to hypertension of chronic kidney disease

Journal of Hypertension

Volumn 32, Issue 7, 2014, Pages 1523-1533

  Papageorgiou, Peter C ^a,b   Chan, Christopher T ^a,b   Yeo, Erik L ^b   Backx, Peter H ^a,b,c   Floras, John S ^a,b  

^a HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chronic renal failure; Coagulation Fxiia; Hypertension; Kinin kallikrein system

Indexed keywords

ADRENALIN; ANTIHYPERTENSIVE AGENT; BLOOD CLOTTING FACTOR 12A; KININOGEN; NORADRENALIN; KININ;

ADRENALIN BLOOD LEVEL; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BROWN NORWAY RAT; CATECHOLAMINE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KALLIKREIN KININ SYSTEM; MALE; MEAN ARTERIAL PRESSURE; NEPHRECTOMY; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; RAT; UREMIA; VASCULAR RESISTANCE; VASOCONSTRICTION; ANIMAL; BLOOD; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE MODEL; HYPERTENSION, RENAL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY;

ADULT; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; FACTOR XIIA; FEMALE; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; KININS; MALE; MIDDLE AGED; RATS; RATS, INBRED BN; RENAL DIALYSIS; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 84903895128     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000192     Document Type: Article

References (49)

1. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. FXII. Blut 1990; 61:258-266
2. Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010; 125:210-215
3. Amfilochiadis AA, Papageorgiou PC, Kogan N, Boomsma F, Osmond DH. Role of bradykinin B2-receptor in the sympathoadrenal effects of 'New Pressor Protein' related to human blood coagulation factor XII fragment. J Hypertens 2004; 22:1173-1181
4. Papageorgiou PC, Pourdjabbar A, Amfilochiadis AA, Diamandis EP, Boomsma F, Osmond DH. Are cardiovascular and sympathoadrenal effects of human 'new pressor protein' preparations attributable to human coagulation beta-FXIIa? Am J Physiol Heart Circ Physiol 2004; 286:H837-H846
5. Papageorgiou PC, Simos D, Boomsma F, Rojkjaer R, Osmond DH. Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIa. Can J Cardiol 2009; 25:e100-e108
6. Mavrogiannis L, Trambakoulos DM, Boomsma F, Osmond DH. The sympathoadrenal system mediates the blood pressure and cardiac effects of human coagulation factor XII-related 'new pressor protein'. Can J Cardiol 2002; 18:1077-1086
7. Amfilochiadis AA, Backx PH, Floras JS. Adrenomedullary catecholamine, pressor and chronotropic responses to human coagulation beta-FXIIa mediated by endogenous kinins. J Hypertens 2008; 26:61-69
8. Hayashi I, Hoshiko S, Makabe O, Oh-ishi S. A point mutation of alanine 163 to threonine is responsible for the defective secretion of high molecular weight kininogen by the liver of brown Norway Katholiek rats. J Biol Chem 1993; 268:17219-17224
9. Papageorgiou PC, Yeo EL, Backx PH, Floras JS. Activated plasma coagulation ß-factor XII-induced vasoconstriction in rats. Clin Sci 2012; 122:581-590
10. Patrassi GM, Fallo F, Martinelli S, Mantero F, Boeri G, Girolami A. The contact phase of blood coagulation and renin activation in essential hypertension before and after captopril. Eur Heart J 1984; 5:561- 567
11. Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13:783-788
12. Colhoun HM, Zito F, Norman Chan N, Rubens MB, Fuller JH, Humphries SE. Activated factor XII levels and factor XII 46C > T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 2002; 163:363-369
13. Lowe GD, Rumley A, McMahon AD, Ford I, O'Reilly DS, Packard CJ. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24:1529-1534
14. Ponitz V, Brugger-Andersen T, Pritchard D, Grundt H, Staines H, Nilsen DW. Activated factor XII type A predicts long-term mortality in patients admitted with chest pain. J Thromb Haemost 2009; 7:277- 287
15. Matsuo T, Koide M, Kario K, Suzuki S, Matsuo M. Extrinsic coagulation factors and tissue factor pathway inhibitor in end-stage chronic renal failure. Haemostasis 1997; 27:163-167
16. Ford RP, Esnouf MP, Burgess AI, Sarphie A. An enzyme-linked immunosorbent assay (ELISA) for the measurement of activated factor XII (Hageman factor) in human plasma. J Immunoassay 1996; 17:119-131
17. Nevard CH, Jurd KM, Lane DA, Philippou H, Haycock GB, Hunt BJ. Activation of coagulation and fibrinolysis in childhood diarrhoeaassociated haemolytic uraemic syndrome. Thromb Haemost 1997; 78:1450-1455
18. Onesti G, Kim KE, Greco JA, del Guercio ET, Fernandes M, Swartz C. Blood pressure regulation in end-stage renal disease and anephric man. Circ Res 1975; 36:145-152
19. Pearl RJ, Papageorgiou PC, Goldman M, Amfilochiadis AA, Boomsma F, Rojkjaer R, et al. Possible role of new pressor protein in hypertensive anephric hemodialysis patients. Pediatr Nephrol 2003; 18:1025- 1031
20. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS. Shortterm blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 2003; 42:925-931
21. Salmon J, Cardigan R, Mackie I, Cohen SL, Machin S, Singer M. Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways. Intensive Care Med 1997; 23:38-43
22. Esnouf MP, Burgess AI, Dodds AW, Sarphie AF, Miller GJ. A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C1 esterase inhibitor. Thromb Haemost 2000; 83:874-881
23. Loeb WF, Quimby FW. The clinical chemistry of laboratory animals. Philadelphia: Taylor and Francis, CRC Press; 1999
24. Papageorgiou PC, Yeo EL, Backx PH, Floras JS. A new enzyme-linked immunosorbent assay recognizing both rat and human activated coagulation Factor XII (FXIIa). J Immunol Methods 2012; 376:132- 138
25. Weir TB, Smith CC, Round JM, Betteridge DJ. Stability of catecholamines in whole blood, plasma, and platelets. Clin Chem 1986; 32:882- 883
26. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006; 203:513-518
27. Walshe KJ, Mackie IJ, Gallimore M, Machin SJ. A microtitre chromogenic substrate assay for factor XII. Thromb Res 1987; 47:365-371
28. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348:101-108
29. Ots M, Troy JL, Rennke HG, Mackenzie HS, Brenner BM. Impact of the supplementation of kidney mass on blood pressure and progression of kidney disease. Nephrol Dial Transplant 2004; 19:337-341
30. Dendorfer A, Hauser W, Falias D, Dominiak P. Bradykinin increases catecholamine release via B2 receptors. Pflugers Arch 1996; 432:R99- R106
31. Walker K, Perkins M, Dray A. Kinins and kinin receptors in the nervous system. Neurochem Int 1995; 26:1-16; discussion 17-26
32. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009; 20:933-939
33. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979
34. Hoagland KM, Maddox DA, Martin DS. Intrarenal infusion of bradykinin elicits a pressor response in conscious rats via a B2-receptor mechanism. Can J Physiol Pharmacol 1999; 77:563-570.
35. Hoagland KM, Maddox DA, Martin DS. Bradykinin B2-receptors mediate the pressor and renal hemodynamic effects of intravenous bradykinin in conscious rats. J Auton Nerv Syst 1999; 75:7-15
36. Fasciolo JC, Vargas L, Lama MC, Nolly H. Bradykinin-induced vasoconstriction of rat mesenteric arteries precontracted with noradrenaline. Br J Pharmacol 1990; 101:344-348
37. Jolma P, Kalliovalkama J, Tolvanen JP, Koobi P, Kahonen M, Saha H, Porsti I. Preserved endothelium-dependent but impaired beta-adrenergic relaxation of the resistance vessels in experimental renal failure. Exp Nephrol 2002; 10:348-354
38. Mimura T, Hayashi I, Hoshino T, Oh-ishi S. Demonstration of highmolecular- weight kininogen in kininogen-deficient rat kidneys. J Biochem 1994; 116:59-63
39. Rhaleb NE, Yang XP, Nanba M, Shesely EG, Carretero OA. Effect of chronic blockade of the kallikrein-kinin system on the development of hypertension in rats. Hypertension 2001; 37:121-128
40. Liu YH, Yang XP, Mehta D, Bulagannawar M, Scicli GM, Carretero OA. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. Am J Physiol Heart Circ Physiol 2000; 278:H507-514
41. Katori M, Majima M. The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension. Crit Rev Clin Lab Sci 2003; 40:43-115
42. Soriano S, Gonzalez L, Martin-Malo A, Rodriguez M, Aljama P. Creactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. Clin Nephrol 2007; 67:352-357
43. Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37:375-381
44. Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118:3208-3218
45. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63:1934- 1943
46. Crews DC, Plantinga LC, Miller ER 3rd, Saran R, Hedgeman E, Saydah SH, et al. Prevalence of chronic kidney disease in persons with undiagnosed or prehypertension in the United States. Hypertension 2010; 55:1102-1109
47. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003; 325:163-167
48. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Agespecific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913
49. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53:860-866.